Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

  • Erika P. Navarro-Mendoza
  • Gabriel J. Tobón
Vasculitis (L Espinoza, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Vasculitis


Purpose of review

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide.

Recent findings

With the right treatment, clinical prognosis is favorable, so concerted efforts have been made in recent years to find new alternatives for treating severe EGPA. Monoclonal antibodies such as omalizumab, rituximab, and mepolizumab are among these new options.


This review summarizes the pathogenesis and clinical manifestations of EGPA and critically examines current and emerging therapies.


Churg−Strauss syndrome Therapeutics Rituximab Omalizumab Mepolizumab 


Compliance With Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11. The current consensus is achieved to describe clinical, radiological, and histological aspects useful in daily practice. PubMedGoogle Scholar
  2. 2.
    Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926–35.CrossRefPubMedGoogle Scholar
  3. 3.
    Valent P, Klion AD, Horny H, Roufosse F, Gotlib J. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130:607–12.e9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Watts RA, Lane S. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 2005;19:191–207.CrossRefPubMedGoogle Scholar
  5. 5.
    Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art. Allergy. 2013;68:261–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277–301.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Somer T, Finefold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis. 1995;20:1010–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, et al. HLA–DRB4 as a genetic risk factor for Churg–Strauss syndrome. Arthritis Rheum. 2007;56:3159–66.CrossRefPubMedGoogle Scholar
  9. 9.
    Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg–Strauss syndrome. Clin Exp Rheumatol. 2011;29:S23–34.PubMedGoogle Scholar
  10. 10.
    Schneeweis C, Rafalowicz M, Feist E, Buttgereit F, Rudolph PE, Burmester GR, et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol. 2010;28:62–6.PubMedGoogle Scholar
  11. 11.
    Mouthon L, Dunoque B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48-49:99–103.CrossRefPubMedGoogle Scholar
  12. 12.
    • Jakiela B, Szczeklik W, Plutecka H, Sokolowska B, Mastalerz L, Sanak M, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford). 2012;51:1887–93. This paper demonstrates the role of Th2 and Il5 in the pathogenesis of EGPA. CrossRefGoogle Scholar
  13. 13.
    •• Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92. Describes the consensus of the Chapel Hill nomenclature for systemic vasculitis. CrossRefPubMedGoogle Scholar
  14. 14.
    Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin N Am. 1995;21:911–47.Google Scholar
  15. 15.
    Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, et al. Churg-Strauss syndrome. Autoimmun Rev. 2015;14:341–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine (Baltimore). 1984;63:65–81.CrossRefGoogle Scholar
  17. 17.
    Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–100.CrossRefPubMedGoogle Scholar
  18. 18.
    Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis. 2008;67:1004–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg–Strauss Syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75:17–28.CrossRefGoogle Scholar
  20. 20.
    Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Pagnoux C, Guilpain P, Guillevin L. Churg–Strauss syndrome. Curr Opin Rheumatol. 2007;19:25–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–9.CrossRefPubMedGoogle Scholar
  23. 23.
    De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2009;150:670–80.CrossRefPubMedGoogle Scholar
  24. 24.
    Pagnoux C, Quéméneur T, Ninet J, Perrodeau E, Diot E, Kyndt X, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67:1117–27.CrossRefPubMedGoogle Scholar
  25. 25.
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. Randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.CrossRefPubMedGoogle Scholar
  26. 26.
    Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.CrossRefPubMedGoogle Scholar
  27. 27.
    Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Puéchal X, Pagnoux C, Baron G, French Vasculitis Study Group, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175–86.CrossRefPubMedGoogle Scholar
  29. 29.
    •• Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, et al. Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open. 2017;3:e000449. This paper makes the EULAR/ERA-EDTA treatment focus recommendations for EGPA patients based on level evidence. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis. 2004;63:1649–5.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA associated renal vasculitis. N Engl J Med. 2010;363:211–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA associated vasculitis. N Engl J Med. 2010;363:221–32.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA associated vasculitis. N Engl J Med. 2013;369:417–27.CrossRefPubMedGoogle Scholar
  34. 34.
    Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg−Strauss syndrome). Arthritis Res Ther. 2013;15:R133.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract. 2017;5:1555–63.CrossRefGoogle Scholar
  36. 36.
    Mohamad AJ, Hot A, Arndt F, Moosiq F, Guerry MJ, Amudala N, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75:396–401.CrossRefGoogle Scholar
  37. 37.
    Aguirre- Valencia D, Posso-Osorio I, Bravo JC, Bonilla- Abadía F, Tobón GJ, Cañas CA. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol. 2017;36:2159–62.CrossRefPubMedGoogle Scholar
  38. 38.
    Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117:1493–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007;144:155–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53:201–6.CrossRefPubMedGoogle Scholar
  41. 41.
    • Jachiet M, Samson M, Cottin M, Kahn JE, Le Guenno G, Bonniaud P, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Rheumatol. 2016;68:2274–82. This is the largest study which used omalizumab in EGPA patients. CrossRefPubMedGoogle Scholar
  42. 42.
    Nazir S, Tachamo N, Fareedy SB, Khan MS, Lohani S. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol. 2017;118:372–4.e1.CrossRefPubMedGoogle Scholar
  43. 43.
    Bekçibaşı M, Barutçu S, Çelen MK, Dayan S, Hoşoğlu S. Churg-Strauss syndrome occurring during omalizumab treatment. Eur J Rheumatol. 2015;2:129–30.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Cisneros C, Segrelles G, Herráez L, Gonzalez A, Girón R. Churg-Strauss syndrome in a patient treated with omalizumab. J Investig Allergol Clin Immunol. 2013;23:515–6.PubMedGoogle Scholar
  45. 45.
    Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136:507–18.CrossRefPubMedGoogle Scholar
  46. 46.
    Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008;19:364–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Gauvreau GM, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I. QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: results from a predictive modeling study. Eur Respir J. 2015;46:PA5091.CrossRefGoogle Scholar
  48. 48.
    Bagnasco D, Ferrando M, Varricchhi G, Puggioni F, Passalacqua G, Canonica GW. Anti-interleukin 5 (iL-5) and iL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.CrossRefGoogle Scholar
  49. 49.
    Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:267–70.CrossRefPubMedGoogle Scholar
  50. 50.
    Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid sparing treatment option in patients with Churg–Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336–43.CrossRefPubMedGoogle Scholar
  51. 51.
    Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg–Strauss syndrome. Ann Intern Med. 2011;155:341–3.CrossRefPubMedGoogle Scholar
  52. 52.
    Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30:S62–5.PubMedGoogle Scholar
  53. 53.
    •• Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–32. This is the first multicenter double-blind randomized clinical controlled trial that investigates remission in EGPA patient using mepolizumab. CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Guillevin L. Vasculitis: mepolizumab for eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2017;13(9):518–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Beck L, Diamant T, Hamilton J, Graham N, Bieber T, Rocklin R, et al. Dupilumab in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Erika P. Navarro-Mendoza
    • 1
  • Gabriel J. Tobón
    • 1
    • 2
  1. 1.GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Fundación Valle del LiliUniversidad IcesiCaliColombia
  2. 2.Immunology LaboratoryFundación Valle del LiliCaliColombia

Personalised recommendations